Skip to main content

Advertisement

We’d like to understand how you use our websites in order to improve them. Register your interest.

New clinical results with sGC stimulators

Background

Stimulators of the nitric oxide (NO) receptor soluble guanylate cyclase (sGC) are a new class of substances which enhance the biosynthesis of cyclic guanosin - monophosphate (cGMP) independently from the presence of nitric oxide (NO). In pulmonary smooth muscle cells, increased intracellular cGMP concentrations lead to vasodilatation, making sGC-stimulators potentially useful for the treatment of patients suffering from pulmonary hypertension (PH). Despite recent advances in the management of PH there is still significant morbidity and mortality from this condition which may occur in isolation (idiopathic pulmonary arterial hypertension, iPAH) or in the context of different clinical settings including chronic thromboembolic pulmonary hypertension (CTEPH), PH in chronic obstructive pulmonary diseases (PH-COPD), in interstitial lung disease (PH-ILD) or in left heart disease (PH-LHD).

Results

Riociguat is an orally active sGC-stimulator that has been shown to have a favourable tolerability profile. Consequently, Riociguat has been tested in small pilot studies and in one phase II clinical trial in PAH and CTEPH [1] as well as in PH-COPD [2] and PH-ILD [3]. The results of these studies suggest that Riociguat is a potential treatment option for all of these conditions by improving pulmonary hemodynamics. For PAH and CTEPH a positive effect on clinical endpoints including the six minute walking distance has also been demonstrated [1]. As a result phase III clinical trials have been launched for PAH (PATENT-trial), CTEPH (CHEST-trial) and are preparation for the other diseases.

Conclusion

Based on the pharmacologic characteristic and on the preliminary results from phase II studies, Riociguat is a promising new drug which will hopefully be available soon for the treatment of pulmonary hypertension in different patient populations suffering from this condition.

References

  1. 1.

    Ghofrani HA, Hoeper M, Halank M: Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J. 2010, 36: 792-799. 10.1183/09031936.00182909.

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Ghofrani HA, Staehler G, Gruenig E, Halank M, Mitrovic V, Unger S, Mueck W, Frey R, Behr J: The effect of the soluble guanylate cyclase stimulator riocigiuat on hemodynamics in patients with pulmonary hypertension due to chronic obstructive pulmonary disease. Amer J Crit Care Med. 2011, 183: A6127-

    Google Scholar 

  3. 3.

    Hoeper MM, Halank M, Wilkens H, Günther A, Weimann G, Gebert I, Leuchte H, Behr J: Riociguat for patients with pulmonary hypertension associated with interstitial lung disease. Amer J Respir Crit Care Med. 2010, 181: A5262-

    Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Jürgen Behr.

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Behr, J. New clinical results with sGC stimulators. BMC Pharmacol 11, O2 (2011). https://doi.org/10.1186/1471-2210-11-S1-O2

Download citation

Keywords

  • Nitric Oxide
  • Chronic Obstructive Pulmonary Disease
  • Pulmonary Hypertension
  • Pulmonary Arterial Hypertension
  • Interstitial Lung Disease